Progression-free and overall survival outcomes in patients with cancer treated with immunotherapy could be related to thymic ...

Overall survival outcomes in MATTERHORN trial support perioperative durvalumab plus chemotherapy as standard of care.

B ERLIN -- Antibody-drug conjugates (ADCs) targeting Trop2 made a strong case as first-line standard of care for metastatic ...

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, hosted its CRM Summit on 10th–11th October at Conrad Abu Dhabi Etihad Towers.The event brought together more than 300 ...

Boehringer Ingelheim’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC: Ingelheim, Germany Monday, Oc ...

Boehringer Ingelheim, which has so far inked at least five hefty partnerships—including its latest one with South Korea’s ...

As pharmaphorum reported during ESMO 2025, fresh from a return to oncology with the FDA approval of zongertinib as a ...

After charting several related moves earlier this year, Boehringer Ingelheim is returning to the antibody-drug conjugate well ...

According to Boehringer, Hernexeos achieved a 77% objective response rate (OOR) in a cohort of previously untreated HER2+ ...

Accent Therapeutics today announced an asset purchase agreement with Boehringer Ingelheim for a preclinical, potentially ...